the FDA approved prescription medicine for Obstructive Sleep Apnea. Research shows that it considerably improves the level of AHI in patients with OSA. This happens as it activates the two ...

The dual GLP-1 and GIP agonist reduced the apnoea-hypopnoea index (AHI) by up to 63% at 52 weeks, which Lilly said was equivalent to around 30 fewer breathing interruptions per hour. SURMOUNT-OSA ...

Logistic regression analysis showed that only AHI was a predictor of daytime hypercapnia ... daytime hypercapnia may be directly linked to sleep apnea in a subgroup of patients with OSAS.

A study has found that moderate-to-severe obstructive sleep apnea increases risk for incident myocardial infarction between 12 and 5:59 AM.

ILI was associated with an improvement of obstructive sleep apnea, determined by a mean AHI decrease of 9.7 events per hour compared with that in the DSE patient group. Study participants with a ...

IHL-42X is designed to treat OSA by targeting its underlying pathophysiology. An oral fixed-dose combination of dronabinol and acetazolamide, IHL-42X is currently advancing through the RePOSA Phase ...

Moreover, the increased CO levels were normalized by treatment with CPAP in OSA patients ... of CO with hypoxia duration in terms of TST and AHI, the improvement in the oxidative condition ...